Mucopolysaccharidosis (MPS) Treatment Market Segmentation:
Route of Administration Segment Analysis
The intravenous (IV) segment in the mucopolysaccharidosis treatment market is anticipated to garner the largest share of 77.3% by the end of 2035. The segment’s growth is highly attributed to its ability to replace electrolytes and fluids, and replenish blood volume, along with ensuring suitable medications. As per an article published by the National Cancer Institute in May 2025, IV administration for vitamin C caters to doses of more than 500 mg, which in turn leads to increased blood concentrations of ascorbate, in comparison to the oral form. Besides, the June 2022 Clinical Microbiology and Infection report indicated that there are different types of IV antimicrobials that constitute different dosage courses, including 23% for flucloxacillin, 17.2% for piperacillin, 11.6% for vancomycin, and 11% for benzylpenicillin, thus suitable for the segment’s growth.
End user Segment Analysis
The specialty clinics segment in the mucopolysaccharidosis treatment market is expected to cater to the third-largest share by the end of the projected timeline. The segment’s development is highly fueled by the focused nature of MPS care, which demands multiple teams, including metabolic disease specialists, neurologists, and geneticists. Besides, the segment serves as the central facility for administering complicated intravenous biologics, diagnosis, and ensuring coordinated and ongoing patient management. In addition, it is also crucial for administering adverse events and protocols, thereby making specialty clinics the most preferred partner for reimbursed payers and pharmaceutical organizations.
Treatment Segment Analysis
The enzyme replacement therapy (ERT) segment in the mucopolysaccharidosis treatment market is projected to constitute the second-largest share during the forecast timeline. The segment’s upliftment is subject to its importance to effectively aid inherited enzyme deficiencies and lysosomal storage diseases by replacing deficient or missing enzymes and diminishing the buildup of toxic substrate. In this regard, a clinical study was conducted on 221 participants, which was published by Molecular Genetics and Metabolism in July 2025. In the study, misdiagnosed participants received ERT, with a treatment duration of 8.7 years, while the average exposure time of the treatment was 11.7 years, equivalent to 2,197 patient-years.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Subsegments |
|
Route of Administration |
|
|
End user |
|
|
Treatment |
|
|
Type |
|
|
Distribution Channel |
|
|
Therapy Type |
|
